Chemical and Structural Strategies to Selectively Target mTOR Kinase.

ChemMedChem
Chiara BorsariMatthias P Wymann

Abstract

Dysregulation of the mechanistic target of rapamycin (mTOR) pathway is implicated in cancer and neurological disorder, which identifies mTOR inhibition as promising strategy for the treatment of a variety of human disorders. First-generation mTOR inhibitors include rapamycin and its analogues (rapalogs) which act as allosteric inhibitors of TORC1. Structurally unrelated, ATP-competitive inhibitors that directly target the mTOR catalytic site inhibit both TORC1 and TORC2. Here, we review investigations of chemical scaffolds explored for the development of highly selective ATP-competitive mTOR kinase inhibitors (TORKi). Extensive medicinal chemistry campaigns allowed to overcome challenges related to structural similarity between mTOR and the phosphoinositide 3-kinase (PI3K) family. A broad region of chemical space is covered by TORKi. Here, the investigation of chemical substitutions and physicochemical properties has shed light on the compounds' ability to cross the blood brain barrier (BBB). This work provides insights supporting the optimization of TORKi for the treatment of cancer and central nervous system disorders.

References

Feb 18, 1998·The Journal of Pharmacy and Pharmacology·J A GrattonH S Chadha
Sep 1, 1999·Chemistry & Biology·Y LiuK M Shokat
Apr 20, 2001·Journal of Medicinal Chemistry·H van De WaterbeemdD K Walker
Feb 21, 2002·Journal of the American Chemical Society·Sheng DingPeter G Schultz
Jan 27, 2004·Journal of Chemical Information and Computer Sciences·Marc Adenot, Roger Lahana
Mar 31, 2004·European Journal of Medicinal Chemistry·Michael H Abraham
Nov 30, 2004·Journal of Medicinal Chemistry·Paul D Leeson, Andrew M Davis
Feb 19, 2005·Science·D D SarbassovDavid M Sabatini
Mar 23, 2005·Current Opinion in Cell Biology·Matthias P Wymann, Romina Marone
Feb 3, 2006·Cancer Research·Kathryn E O'ReillyNeal Rosen
Feb 21, 2006·NeuroRx : the Journal of the American Society for Experimental NeuroTherapeutics·Hassan Pajouhesh, George R Lenz
Apr 20, 2006·Journal of the National Cancer Institute·Shin-ichi YaguchiTakao Yamori
May 16, 2006·Cancer Cell·Qi-Wen FanWilliam A Weiss
Dec 22, 2006·Journal of Medicinal Chemistry·Stephen A Hitchcock, Lewis D Pennington
Jul 7, 2007·Cancer Cell·David A Guertin, David M Sabatini
Aug 8, 2007·Cell Research·Qian Yang, Kun-Liang Guan
Nov 1, 2007·Nature Reviews. Drug Discovery·Paul D Leeson, Brian Springthorpe
Jan 25, 2008·Nature Reviews. Molecular Cell Biology·Matthias P Wymann, Roger Schneiter
Feb 6, 2008·Bioorganic & Medicinal Chemistry Letters·Frédéric StaufferCarlos García-Echeverría
May 10, 2008·The Biochemical Journal·Jingxiang Huang, Brendan D Manning
Oct 14, 2008·Nature Chemical Biology·Beth ApselZachary A Knight
Jan 16, 2009·Biochemical Society Transactions·Julian R Sampson
Jan 20, 2009·The Journal of Biological Chemistry·Carson C ThoreenNathanael S Gray
Apr 18, 2009·Molecular Cancer Research : MCR·Romina MaroneMatthias P Wymann
Sep 19, 2009·Bioorganic & Medicinal Chemistry Letters·Karine MalaguMartin Pass

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Brain Barrier Chips

The blood brain barrier (BBB) is comprised of endothelial cells that regulate the influx and outflux of plasma concentrations. Lab-on-a-chip devices allow scientists to model diseases and mechanisms such as the passage of therapeutic antibodies across the BBB. Discover the latest research on BBB chips here.

Blood Brain Barrier

The blood brain barrier is a border that separates blood from cerebrospinal fluid. Discover the latest search on this highly selective semipermeable membrane here.

© 2021 Meta ULC. All rights reserved